Anti-phospho-Epidermal Growth Factor Receptor (pTyr⁹⁹²) antibody produced in rabbit

The members of epidermal growth factor receptor (EGF R) or the ErbB receptor family have been identified as useful biomarkers and targets for cancer therapy. The EGFR family includes four receptor tyrosine kinases, EGF R (ErbB1), ErbB2 (neu), ErbB3, and ErbB4. EGF R binds EGF and induces tyrosine phosphorylation leading to proliferation of cells. EGF R is present on many cell types of epithelial and mesenchymal lineages. EGF R is capable of binding transforming growth factor-α and heparin-binding EGF in addition to EGF. There are numerous effector molecule activated by EGF R that result in a variety of biological processes such as morphogenesis, cell motility, apoptosis, differentiation and organ repair and maintenance. Deregulation of EGF R signaling is implicated in progression of a wide variety of tumors, invasion and metastasis. Tyrosine 992 of EGF R is autophosphorylation site and required for increasing the signalling capacity of EGF R
Anti-phospho-EGFR [pTyr⁹⁹²] specifically recognizes human EGFR phosphorylated at tyrosine 992 (~185 kDa). Cross reactivity may be observed with mouse, rat and chicken.

synthetic phosphopeptide derived from the region of human EGFR that contains tyrosine 992. The sequence is conserved in mouse and rat with 100% homology. Chicken EGFR is 80% homologous.

Anti-phospho-EGFR [pTyr⁹⁹²] antibody may be used at a working dilution of 1:1000 for immunoblotting using A431 cells.

Solution in Dulbecco′s phosphate buffered saline (without Mg²⁺ and Ca²⁺) containing 50% glycerol with 1 mg/mL BSA (protease and IgG-free) and 0.05% sodium azide.